Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Haegarda is a medicine made from human C1 esterase inhibitor. It is used regularly to prevent hereditary angioedema attacks in people aged 6 years and older. It is not used to treat an attack that has already started.
read more about haegarda ...Hereditary angioedema can involve too little working C1 inhibitor. Haegarda supplies this protein to help control processes that lead to swelling. Regular treatment reduces the chance of attacks but does not replace an emergency treatment plan.
Haegarda comes as a powder that must be mixed before injection under the skin. The labeled dose is based on body weight and given twice weekly, three or four days apart. A patient or caregiver can give it after receiving training.
Reactions at the injection site can occur. A severe allergic reaction requires immediate medical treatment. Tell your clinician about a history of serious reactions to C1 inhibitor products.
An attack can still occur during preventive treatment. Keep access to the rescue treatment prescribed for you. Swelling involving the throat requires immediate medical attention.
No. Haegarda is for routine prevention, so use the separate rescue plan provided by your clinician for an acute attack.
It is injected under the skin twice weekly. The labeled interval is every three or four days.
It is indicated for patients aged 6 years and older. A clinician calculates the dose from body weight.
A patient or caregiver can administer it after training in preparation and injection. Follow the product instructions and the treatment plan.
C1 esterase inhibitor, human (intravenous route, subcutaneous route) - Side effects & dosage. Mayo Clinic. https://www.mayoclinic.org/drugs-supplements/c1-esterase-inhibitor-human-intravenous-route-subcutaneous-route/description/drg-20072383. Date Accessed October 6, 2026.
C1-Esterase Inhibitor Human Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a622016.html. Date Accessed October 6, 2026.
HAEGARDA. U.S. Food and Drug Administration. https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/haegarda. Date Accessed October 6, 2026.
HAEGARDA (C1 Esterase Inhibitor Subcutaneous [Human]): Prescribing Information. CSL Behring. https://labeling.cslbehring.com/PI/US/HAEGARDA/EN/HAEGARDA-Prescribing-Information.pdf. Date Accessed October 6, 2026.
Haegarda--a subcutaneous C1 esterase inhibitor for prevention of hereditary angioedema. PubMed. https://pubmed.ncbi.nlm.nih.gov/29485978/. Date Accessed October 6, 2026.